According to the Zhitong Finance App, Oukangweishi Bio-B (01477) announced that the group's fluorine intravitreal implants have recently been approved by the China Drug Administration for production in mainland China.

The product submitted a registration application under the Class 4 chemical drug route and was included in the priority review and approval process for drug marketing licenses by the State Drug Administration; its production technology was obtained by the Group through technology transfer, and process transfer and process verification have been completed.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.